Safest Dopaminergic / Anti-prolactin Drug?

[Luckytype]

I Slashed My Prolactin And Doubled My Vitamin D In 12 Weeks - Here Is How

 

[Mauritio]

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. - PubMed - NCBI
It would be nice to figure dosage. Heart problems seems to be an issue on high dosages.
I started experimenting with cabergoline, 0.125mg two times per week

This study has also not found a correlation .

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma

Hundred (61 females, 39 males) prolactinoma cases (81 macroprolactinoma and 19 microprolactinoma) were included in the study. The mean age at presentation was 33.9 ± 9.0 years (range: 16–58 years). The mean duration of treatment was 53.11 ± 43.15 months (range: 12–155 months). The mean cumulative dose was 308.6 ± 290.2 mg (range: 26–1196 mg; interquartile range: 104–416 mg). Mild mitral regurgitation was present in one patient (cumulative cabergoline dose 104 mg). Mild tricuspid regurgitation was present in another two patients (cumulative cabergoline dose 52 mg and 104 mg). Aortic and pulmonary valve functioning was normal in all the cases. There were no cases of significant valvular regurgitation (moderate to severe, Grade 3–4). None of the patients had morphological abnormalities such as thickening, calcification, and restricted mobility of any of the cardiac valves.

 

[Mauritio]

Our results are in accordance to the previously published studies [Tables [Tables11 and and2].2]. Approximately, 2000 prolactinoma patients on cabergoline (cumulative dose-mean: 152–465 mg, range: 15–3385 mg) have been studied for cardiac valvulopathy.[5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27] None of the studies except one[10] have reported a higher prevalence of significant valvular regurgitation in cabergoline exposed prolactinoma patients compared to controls. In the study described by Colao et al.,[10] cabergoline exposed prolactinoma patients had significantly higher prevalence of moderate TR (54%) than healthy controls (0%). Patients treated with a higher cumulative dose (>280 mg) had higher prevalence of moderate TR (72%) than those treated with a lower dose (36%) (P = 0.023). These finding of this group have been distinctly unique and have not been replicated by other studies. Further Colao et al. in a prospective study of 40 patients followed over 5 years did not found any significant valvular lesions.

 

[southcesar]

I have been taking a small dose of Cyproheptadine every night. I don't feel the high dopamine sensation they talk about so much, I just get dissonant.